PD09-05: SU2C Phase Ib Study of pan-PI3K Inhibitor BKM120 Plus Aromatase Inhibitor Letrozole in ER+/HER2− Metastatic Breast Cancer (MBC).
Mayer I, Balko J, Kuba M, Sanders M, Yap J, Li Y, Winer E, Arteaga C. PD09-05: SU2C Phase Ib Study of pan-PI3K Inhibitor BKM120 Plus Aromatase Inhibitor Letrozole in ER+/HER2− Metastatic Breast Cancer (MBC). Cancer Research 2011, 71: pd09-05-pd09-05. DOI: 10.1158/0008-5472.sabcs11-pd09-05.Peer-Reviewed Original ResearchPan-PI3K inhibitor BKM120Metastatic breast cancerFDG-PET imagingAromatase inhibitorsBreast cancerSafe side effect profilePhase Ib clinical trialAlternative administration schedulesDiagnostic tumor biopsiesGrade 3 transaminitisMost common toxicitiesPI3K-targeted therapiesSafety/tolerabilityPhase Ib studyMetastatic bone diseaseSide effect profileMonths of initiationPost-menopausal patientsWeeks of treatmentPI3K pathway inhibitionMost breast cancersAromatase inhibitor letrozoleProgression of diseasePI3K/AktCommon toxicities